CHICAGO — Once-daily sepetaprost was noninferior to twice-daily timolol in reducing IOP in patients with primary open-angle glaucoma or ocular hypertension, according to a study presented at the American Academy of Ophthalmology meeting.
David L. Wirta, MD, and colleagues wrote in a poster presentation that FP receptor agonists can be effective for managing elevated IOP, but not all patients respond to treatment.
“Sepetaprost is a novel investigational prodrug that targets two prostaglandin receptors, FP and EP3,” they wrote.
The randomized, double-masked, controlled phase 2